UCB SA (ETR:UNC)

Market Cap	49.78B
Revenue (ttm)	6.85B +25.6%
Net Income	1.33B +455.0%
EPS	6.87 +462.0%
Shares Out	n/a
PE Ratio	37.37
Forward PE	28.52
Dividend	0.97 (0.38%)
Ex-Dividend Date	Apr 25, 2025

Volume	34
Average Volume	96
Open	256.50
Previous Close	252.80
Day's Range	256.50 - 256.50
52-Week Range	203.00 - 265.30
Beta	n/a
RSI	62.13
Earnings Date	Feb 26, 2026

About UCB SA

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company’s primary products include Cimzia for inflammatory TNF-mediated diseases, as well as ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson’s disease and restless legs syndrome. It also provides Nayzilam, a nasal spra...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1925
• Employees: 8,600
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: UNC

Financial Performance

In 2024, UCB SA's revenue was 6.15 billion, an increase of 18.72% compared to the previous year's 5.18 billion. Earnings were 1.07 billion, an increase of 210.50%.